Meda AB
http://www.meda.se/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Meda AB
Lilly Is Growing Its Next Crop Of Blockbusters
The pharma is digging deeper with early- and mid-stage R&D in age-related neurodegeneration, diabetes/obesity and other priority areas.
Asia Deal Watch: CJ Group Continues Spree With Majority Stake Acquisition In Batavia Biosciences
Plus deals involving Zai Lab/Karuna, Zai Lab/Blueprint, Lotus/PharmaMar, Nippon Shinyaku/Dynacure, Alphamab/Ascletis, Aptose/Hanmi, Shanghai Pharmaceuticals/HUYABIO, KoBioLabs/SPH Sine, CURACLE/ Théa Open Innovation, Signet/XtalPi, Curi Bio/NEXEL, CANbridge/Scriptr and Ligand/CRDC.
Asia Deal Watch: Innovent And Bolt Collaborate On Immune-Stimulating Antibody Conjugates
Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.
Lilly Adds To Diabetes Pipeline With Protomer Buyout
After investing in the California biotech, Lilly buys the company in search of safer insulin products. The pharma sees these candidates as pairing with tirzepatide to improve diabetes therapy overall.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Acton Pharmaceuticals, Inc.
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Madaus Pharma
- Rottapharm Madaus
- Meda Pharmaceuticals Inc.